Phase 2 trial reports an H5N8 flu vaccine candidate raised antibodies in most adults tested
A peer-reviewed phase 2 trial published on 7 November 2026 found two doses of an MF59-adjuvanted H5N8 vaccine raised antibodies in most of 239 vaccinated adults, including people 65 and older. The study measured immune responses, not whether the vaccine prevents…